Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 5/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | GMNN | O75496 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3023323 | 0.85 | TSPO (0.64) | TSPO | |
| SCHEMBL3027773 | 0.82 | TSPO (0.60) | TSPOGMNNLMNAPOLBCYP3A4 | |
| SCHEMBL3023235 | 0.81 | TSPO (0.73) | TSPOGMNNLMNAPOLBCYP3A4 | |
| SCHEMBL3033415 | 0.76 | TSPO (0.85) | TSPOGMNNLMNAPOLBCYP3A4 | |
| SCHEMBL3023239 | 0.75 | TSPO (0.70) | TSPOGMNNLMNAPOLBCYP3A4 | |
| SCHEMBL3027377 | 0.74 | TSPO (0.58) | TSPO | |
| SCHEMBL3033119 | 0.74 | TSPO (0.73) | TSPOGMNNLMNAPOLBCYP3A4 | |
| SCHEMBL3027449 | 0.73 | TSPO (1.00) | TSPOGMNNLMNAPOLBCYP3A4 | |
| SCHEMBL3032865 | 0.71 | TSPO (0.67) | TSPOGMNNLMNAPOLBCYP3A4 | |
| SCHEMBL13217886 | 0.71 | TSPO (0.64) | TSPOGMNNLMNAPOLBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2752415-B1 | Fluorinated ligands for targeting peripheral benzodiazepine receptors | AUSTRALIAN NUCLEAR SCIENCE & TECH ORGANISATION (AU) | 2017-10-11 | — | — | EP | disclosed |
| EP-2752415-A1 | Fluorinated ligands for targeting peripheral benzodiazepine receptors | AUSTRALIAN NUCLEAR SCIENCE & TECHNOLOGY ORGANISATION (AU) | 2014-07-09 | — | — | EP | disclosed |
| US-20100209345-A1 | Fluorinated Ligands for Targeting Peripheral Benzodiazepine Receptors | AUSTRALIAN NUCLEAR SCIENCE & TECHNOLOGY ORGANISATION | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100209345-A1 | Fluorinated Ligands for Targeting Peripheral Benzodiazepine Receptors | GABRA6, GABRA1, GABRA2 | TSPO 41/4885L3MBTL1 2070/4885RAB9A 1716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.